bimagrumab tirzepatide Concentration–time profile of in healthy older adults and 💉 Bimagrumab: “BELIEVE or not

The proportion of patients who discontinued for lack of glycemic control or who were rescued for meeting prespecified glycemic criteria was 10% in the saxagliptin 2.5 mg add-on to TZD group, 6% for the saxagliptin 5 mg add-on to TZD group, and 10% in the placebo add-on to TZD group

Wegovy: Subcutaneous injection approved by the FDA on June 4, 2021, for chronic weight management in patients with obesity (body mass index of 30 or more) and overweight (body mass index of 27 or more) with a weight-related condition like cardiovascular disease, high blood pressure, or type 2 diabetes

Yu, D., Shu, X.-O., Xiang, Y.-B., Li, H., Yang, G., Gao, Y.-T., Zheng, W., & Zhang, X

doi: 10.2471/BLT.17.198358 174